Compare ONL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONL | SGMT |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 169.4M |
| IPO Year | 2021 | 2021 |
| Metric | ONL | SGMT |
|---|---|---|
| Price | $2.75 | $7.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $3.00 | ★ $26.13 |
| AVG Volume (30 Days) | 627.1K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,647,000.00 | $2,000,000.00 |
| Revenue This Year | $4.10 | N/A |
| Revenue Next Year | $3.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $4.50 |
| 52 Week High | $3.04 | $11.41 |
| Indicator | ONL | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 54.97 |
| Support Level | $2.62 | $7.09 |
| Resistance Level | $2.98 | $7.95 |
| Average True Range (ATR) | 0.11 | 0.45 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 40.26 | 57.48 |
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.